Evidence map›Paper›PMID 27211563›Full record

ArticleEBioMedicine2016

HnRNP A1 is Involved in Deep Vein Thrombosis Patients with Behçet's Disease.

Peng Chen, Chunyan Zhang, Chen Liu, Liyun Zhang, Chunhe Yang, Guangyu Chen, Dan Ma, Yaping Tian, Hongwu Du

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Peng Chen112 Lab, School of Chemistry and Biotechnology Engineering, University of Science & Technology Beijing, Beijing 100083, China.
Chunyan ZhangDepartment of Clinical Biochemistry, Chinese PLA General Hospital, Beijing 100853, China.
Chen Liu112 Lab, School of Chemistry and Biotechnology Engineering, University of Science & Technology Beijing, Beijing 100083, China.
Liyun ZhangRheumatology Department of Shanxi DaYi Hospital, Shanxi Academy of Medical Sciences, Taiyuan 030032, China.
Chunhe Yang112 Lab, School of Chemistry and Biotechnology Engineering, University of Science & Technology Beijing, Beijing 100083, China.
Guangyu ChenImmunoHunt Corporation, Beijing 100070, China.
Dan MaRheumatology Department of Shanxi DaYi Hospital, Shanxi Academy of Medical Sciences, Taiyuan 030032, China.
Yaping TianDepartment of Clinical Biochemistry, Chinese PLA General Hospital, Beijing 100853, China. Electronic address: tianyp61@gmail.com.
Hongwu Du112 Lab, School of Chemistry and Biotechnology Engineering, University of Science & Technology Beijing, Beijing 100083, China. Electronic address: hwdu93@126.com.
University of Science and Technology Beijing · CNChinese PLA General Hospital · CNShanxi Dayi Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this study was to verify the hypothesis originated from bioinformatics and literature reviews that hnNRP A1 may be a new immune target of Behçet's disease (BD).

methodsFirst, bioinformatics was used to show the correlation between hnRNP A1 and A2/B1 in amino acid sequences and three dimensional structures. Second, hnRNP A1 was expressed, purified, and immunologically confirmed by systematic immunology methods including: Western blotting, immunoprecipitation and Dot-ELISA. Then, ELISA was used to screen the anti-hnRNP A1 autoantibodies in newly confirmed clinical samples and the clinical significance was compared between anti-hnRNP A1 antibody positive and negative groups. Finally, the endothelial cells antigen profile of one anti-hnRNP A1 antibody positive BD patient was detected using immunoprecipitation with liquid chromatography tandem mass spectrometry (LC-TMS).

resultsIn total 720 subjects enrolled and tested in this study. Our results demonstrated hnRNP A1 as a new immune target of BD. The reactivity of BD serum IgG antibodies against hnRNP A1 was significantly higher than healthy controls (P<0.0001), and deep vein thrombosis (DVT) showed a significant higher in the anti-hnRNP A1 antibodies positive group (P<0.05).

Indexed as

AdolescentAdultAgedAged, 80 and overAmino Acid SequenceAutoantibodiesBehcet SyndromeComputational BiologyFemaleHeterogeneous Nuclear Ribonucleoprotein A1Heterogeneous-Nuclear Ribonucleoprotein Group A-BHumansHuman Umbilical Vein Endothelial CellsMaleMiddle AgedVenous ThrombosisAutoantibodiesHeterogeneous Nuclear Ribonucleoprotein A1Heterogeneous-Nuclear Ribonucleoprotein Group A-BAutoantigenBehçet's diseaseBioinformaticsHnRNP A1

Identifiers

PMID27211563
PMCPMC4856785
OpenAlexW2294992969

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.